Baidu
map

J Hepatol:直接抗病毒药物治疗导致HCV清除后,可改善患者颈动脉粥样硬化

2018-03-08 MedSci MedSci原创

DAA治疗导致HCV清除,改善了严重纤维化患者的颈动脉粥样硬化,而未增加代谢危险因素。从长期来看,动脉粥样硬化负担的改善对主要心血管疾病的减少的影响是值得研究的。 原始出处

研究背景:最近的研究表明,HCV感染和心血管损伤(包括颈动脉粥样硬化)相关,HCV的清除可能影响心血管预后。本研究旨在评估采用直接抗病毒治疗清除HCV,是否会改善存在进展性肝纤维化/肝硬化的HCV感染患者的颈动脉粥样硬化的预后。

研究方法:用病毒学、人体测量和代谢测量等方法评估182例患有晚期纤维化或代偿性肝硬化的HCV患者。根据AISF/EASL指南,所有患者都接受了基于DAA的抗病毒治疗。在基线和治疗结束后的9-12个月评估动脉内膜中层厚度(IMT)、颈动脉增厚(IMT≥1 mm)和颈动脉斑块(在颈总动脉的水平上定义为≥1.5 mm的斑点增厚)。

研究结果:56%的患者为男性,平均年龄为63.1±10.4岁,65.9%的患者为代偿性肝硬化。20%的患者为糖尿病患者,14.3%的患者为肥胖患者,41.8%的患者存在高血压,35.2%的患者抽烟。平均IMT为0.94±0.29 mm,42.9%的患者IMT≥1mm,42.9%的患者存在颈动脉斑块。所有的患者在治疗后,获得12周的可持续病毒学应答。从基线到随访,IMT显著下降(0.94+/-0.29 mm vs. 0.81+/-0.27, p<0.001)。从基线到随访,颈动脉增厚的比率显著下降(42.8% vs. 17%, p<0.001),然而,颈动脉斑块未有改变(42.8% vs. 47.8%, p=0.34)。这些结果在因心血管危险因素和肝脏疾病严重程度分层的亚组患者中,得到了证实。

研究结论:DAA治疗导致HCV清除,改善了严重纤维化患者的颈动脉粥样硬化,而未增加代谢危险因素。从长期来看,动脉粥样硬化负担的改善对主要心血管疾病的减少的影响是值得研究的。

原始出处

Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis. J Hepatol, 2018 Mar 2. doi: 10.1016/j.jhep.2018.02.015.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-10 ymljack
  5. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-10 yahu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-10 gwc384
  8. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1944517, encodeId=3db6194451ea7, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Sep 30 01:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843502, encodeId=098a1843502de, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Dec 29 01:15:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967825, encodeId=9752196e8255b, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Nov 08 13:15:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257723, encodeId=0541125e72393, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292417, encodeId=1a6b129241e12, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363342, encodeId=12cf136334235, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427036, encodeId=36f9142e03600, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459366, encodeId=00ff14593668c, content=<a href='/topic/show?id=477610056158' target=_blank style='color:#2F92EE;'>#颈动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100561, encryptionId=477610056158, topicName=颈动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88db6138923, createdName=经常头晕, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489481, encodeId=896814894818b, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Sat Mar 10 12:15:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294443, encodeId=0a22294443b8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:30 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-09 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关资讯

N Engl J Med:Glecaprevir-Pibrentasvir治疗HCV基因1或3型患者,可达到很好的治疗效果

采用glecaprevirp -pibrentasvir治疗无肝硬化的HCV基因1型或基因3型患者8周或12周,可达到很高的可持续病毒学应答率

J Viral Hepat:波兰HCV患者经直接抗病毒药物治疗的疗效和安全性

EpiTer-2研究表明,采用直接抗病毒药物治疗HVC 1型患者,疗效良好,且药物不良反应低;但是,目前治疗方案的弱点是治疗HCV基因3型感染。

Liver Int:HCV-DAA治疗对细胞外囊泡miRNAs含量及免疫调节性能的影响

HCV患者外泌体中调节免疫的microRNA的富集与其对先天免疫细胞功能的抑制作用有关。DAA治疗使CHC患者血浆microRNA的含量减低。与外界相关的microRNA可能会提供有价值的生物标志物来监测免疫反应的恢复。

Liver Int:接受DAA与利巴韦林联合治疗的HCV患者,利巴韦林剂量的调整并不影响治疗效果

DAA联合利巴韦林治疗的HCV患者,在治疗早期经常将利巴韦林的剂量降低;利巴韦林剂量的降低并没有影响可持续病毒学应答率。基线血红蛋白水平较低的HCV患者,在治疗过程中应该检测是否发生贫血

J Viral Hepat:在感染了丙型肝炎的埃及人群中,经DAA治疗后,患者肝细胞癌的复发率增加

研究结果为DAAs在HCC患者复发中的可能作用提供了重要证据,并强调需要进一步的研究和临床试验,以确认这一作用,并确定可能与此事件相关的患者特征。

J Hepatol:DAA药物提高了早期肝移植患者生存率和改善了肝移植候补患者病情

DAA的高疗效与肝硬化候选患者疾病的改善显著相关,尤其重要的是提高了肝移植后患者的生存率

Baidu
map
Baidu
map
Baidu
map